In specialty and rare disease, patient consent is collected across hub services, specialty pharmacies, patient services teams, and digital channels. Yet in most organizations, none of these systems talk to each other. The result: manufacturers can’t reliably know who has consented to outreach, or act on that information at the moment it matters most.
This white paper presents the evidence base for treating consent management as a strategic commercial and clinical function, along with a practical framework for building the infrastructure to get there.
What You’ll Learn:
- The regulatory and operational complexity of consent across a 50-state footprint
- How timing affects abandonment risk and what it means for your patient engagement strategy
- A four-function infrastructure framework for unified, real-time consent governance
- The Consent Maturity Model: four levels, and where most organizations sit today
